Researchers at The Pirbright Institute have developed a new method of genetically modifying the Marek’s disease vaccine so it is also able to protect against other destructive poultry viruses such as infectious bursal disease (IBD), avian influenza or Newcastle disease. This approach could lead to a reduction in the number of vaccines that need to be administered to each bird.
Vaccines that target multiple diseases are in high demand due to the many viruses that can circulate simultaneously in flocks. Protecting against the most dangerous diseases with one vaccine could reduce overall vaccination costs for poultry producers and decrease the number of times that birds need to be handled.
The new research conducted by Pirbright scientists has demonstrated that a gene editing system called CRISPR/cas9 can be used to insert a gene of the IBD virus into the currently used Marek’s disease vaccine virus. The added genetic material protects poultry against IBD in addition to the protection already offered by the Marek’s disease vaccine, meaning that bird owners would only need to use one vaccine instead of two.
Other vaccines generated by conventional methods can achieve a similar result, but by using the CRISPR/cas9 system the Pirbright team have been able to insert the IBD gene far more quickly, easily and accurately than the methods that have been used before. This will significantly reduce the time needed to generate new vaccines.
Professor Venugopal Nair, joint leader of the research at Pirbright said: “The method we have created with CRISPR/cas9 really increases the scope of how we edit the Marek’s disease vaccine to include other virus components. Now we have shown that the gene-edited vaccine protects against both Marek’s disease and IBD, we are looking at inserting more genes from other viruses.”
The team intend to generate a vaccine that will be able to protect against multiple avian diseases and will next target two high consequence poultry viruses - avian influenza virus and the Newcastle disease virus. The flexibility of the new method also means that as the viruses evolve, the vaccine virus can be easily edited to include new genes which protect against emerging strains.
There has been huge commercial interest in using this technology to develop novel vaccines, so Pirbright scientists intend to partner vaccine manufacturing companies to bring CRISPR/cas9 edited vaccines to market.
This scientific paper can be found in the Vaccine journal and was funded by the Biotechnology and Biological Sciences Research Council (BBSRC); grant numbers BB/P016472/1 BB/L014262/1.
ENDS
Note to editors:
This study was generated by the UK-China Centre of Excellence for Research on Avian Diseases (CERAD) collaboration that is funded by the BBSRC-Newton fund. CERAD allows scientists from Pirbright to connect with several research institutes in China for the purpose of generating novel research and sharing skills and expertise.
Further collaboration fostered by CERAD will help to expand Pirbright’s avian vaccine research that targets many of the viruses that are endemic to the poultry industry. Each virus requires separate vaccination, so there is high demand from the poultry industry to reduce the number of administrations needed per bird. This is especially vital in countries such as China, where up to 10 billion chickens are reared for consumption annually.
For more information on the diseases mentioned in this article, please visit The Pirbright Institute virus pages.
Please contact the Pirbright Communications Team if you would like further information or to request an interview with our scientists.
communications@pirbright.ac.uk
Tel: +44 (0) 1483 231120.
Follow The Pirbright Institute on social media: Facebook Twitter
About The Pirbright Institute
The Pirbright Institute is a world leading centre of excellence in research and surveillance of virus diseases of farm animals and viruses that spread from animals to humans. Based in the UK and receiving strategic funding from the Biotechnology and Biological Sciences Research Council (BBSRC), the Institute works to enhance capability to contain, control and eliminate these economically and medically important diseases through highly innovative fundamental and applied bioscience.
With an annual income of nearly £26.1 million from grants and commercial activity, and a total of £5 million strategic investment from BBSRC during 2016-2017, the Institute contributes to global food security and health, improving quality of life for animals and people.
For more information about The Pirbright Institute see: www.pirbright.ac.uk
About BBSRC
BBSRC invests in world-class bioscience research and training on behalf of the UK public. Our aim is to further scientific knowledge, to promote economic growth, wealth and job creation and to improve quality of life in the UK and beyond.
Funded by government, BBSRC invested £469 million in world-class bioscience in 2016-17. We support research and training in universities and strategically funded institutes. BBSRC research and the people we fund are helping society to meet major challenges, including food security, green energy and healthier, longer lives. Our investments underpin important UK economic sectors, such as farming, food, industrial biotechnology and pharmaceuticals.
More information about BBSRC, our science and our impact: https://bbsrc.ukri.org
More information about BBSRC strategically funded institutes: https://bbsrc.ukri.org/research/institutes/strategically-funded-institutes/